Sustaining generic medicines markets in Europe

Journal of Generic Medicines

Volumn 3, Issue 4, 2006, Pages 257-268

  Simoens, Steven ^a   De Coster, Sandra ^b  

^a Research Centre for Pharmaceutical Care and Pharmaco Economics   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

ARTICLE; BUDGET; DRUG COST; DRUG MARKETING; EUROPE; GOVERNMENT REGULATION; HEALTH CARE DELIVERY; PATIENT CARE; PHARMACIST; PHYSICIAN; POLICY; REWARD;

EID: 33846880007     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/palgrave.jgm.4940128     Document Type: Article

References (17)

1. Organisation for Economic Co-operation and Development (2005) 'Health at a Glance: OECD Indicators 2005', Organisation for Economic Co-operation and Development, Paris.
2. European Commission (2004) 'Innovation in the Pharmaceutical Sector', Charles River Associates, Brussels, available at http://pharmacos.eudra.org, accessed 19th January, 2006.
3. Simoens, S. and De Coster, S. (2006) 'Sustaining generic medicines markets in Europe', Katholieke Universiteit Leuven, Leuven, available at http://www.egagenerics.com, accessed 6th April, 2006.
4. IMS Health (2004) 'Midas Database', IMS Health, London.
5. European Generic Medicines Association (2005) '2005 Market Review: The European Generic Pharmaceutical Markets', European Generic Medicines Association, Brussels.
6. European Generic Medicines Association (2005) '2005 Market Review: The European Generic Pharmaceutical Markets', European Generic Medicines Association, Brussels.
7. Directive 1989/105/EEC of 21st December, 1988, relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems, Official Journal of the EU, 11th February, 1989, pp. 8-11.
8. Europe Economics (1998) 'Access to Important New Medicines: Where and Why Do Patients Wait?', Europe Economics, London, available at http://www.eer.co.uk, accessed 15th December, 2005.
9. Cambridge Pharma Consultancy (2002) 'Delays to Market Access in Europe', Cambridge Pharma Consultancy, Cambridge.
10. Schulz, A. (2004) 'Evolving dynamics of US and European generics markets', Journal of Generic Medicines, Vol 2, pp. 23-32.
11. de Joncheere, K., Rietveld, A. H. and Huttin, C. (2002) 'Experiences with generics', International Journal of Risk and Safety of Medicines, Vol. 15, pp. 101-109.
12. King, D. R. and Kanavos, P. (2002) 'Encouraging the use of generic medicines: Implications for transition economies', Croatian Medical Journal, Vol. 43, pp. 462-469.
13. Peny, J. M. (2005) 'Barriers to substitution', Scrip Magazine, Vol. 4, pp. 19-23.
14. Ghislandi, S., Krulichova, I. and Garattini, L. (2005) 'Pharmaceutical policy in Italy: Towards a structural change?', Health Policy, Vol. 72, pp. 53-63.
15. Lopez-Casasnovas, G. and Puig-Junoy, J. (2000) 'Review of the literature on reference pricing', Health Policy, Vol. 54, pp. 87-123.
16. Le Pen, C. (2005) 'Substitution générique et prescription dans le répertoire' (Generic substitution and prescribing practices in the off-patent market), University of Paris-Dauphine, Paris.
17. OsMed (2003) 'Rapporto nazionale OsMed 2003' (National OsMed report 2003), Italian Ministry of Health, Rome, available from http://www.ministerosalute.it/medicinali/osmed, accessed 5th December, 2005.